By Brazil Stock Guide – Oncoclínicas do Brasil (ONCO3) is selling its minority stake in a Saudi Arabian joint venture and agreed to settle a R$ 159.2 million claim against a regional Unimed operator for R$ 90 million, in two moves aimed at raising cash and simplifying its finances during a debt restructuring.
The Brazilian cancer-care group said it signed an agreement on July 31 to sell its entire 27.49% interest in Specialized Medical Treatment Company to Saudi Arabia’s Advanced Drug Company for Pharmaceuticals. The stake comprises 45 million shares, according to a regulatory filing released Monday.
Oncoclínicas did not disclose the sale price, payment terms or the potential accounting impact of the transaction. The absence of a value makes it difficult to assess how much the disposal could contribute to the company’s immediate liquidity needs.
The company said the divestment is part of measures being implemented under its out-of-court restructuring process, filed on July 13 before a bankruptcy and restructuring court in São Paulo.
In a separate filing, Oncoclínicas said its Navarra RJ Serviços Oncológicos subsidiary reached an agreement with Unimed São Gonçalo Niterói, which operates under the Unimed Leste Fluminense brand, to end a debt-enforcement lawsuit.
Navarra had sought R$ 159.18 million after the operator failed to pay installments established under debt-confession agreements. Under the settlement, Unimed Leste Fluminense will pay R$ 90 million, subject to court approval.
The agreement represents a discount of about R$ 69.2 million, or 43.5%, from the amount claimed in court. Still, converting a disputed receivable into cash may be more valuable to Oncoclínicas than pursuing the full amount through a potentially lengthy legal process.
The filing did not say when the R$ 90 million will be paid, whether the amount will be transferred upfront or in installments, or how much of the receivable had already been provisioned. Those details will determine the immediate impact on earnings and cash flow.
Taken together, the Saudi divestment and the Unimed settlement show Oncoclínicas moving on several fronts to generate liquidity, reduce exposure to non-core assets and accelerate the collection of receivables.
The sale also marks a retreat from an international expansion initiative at a time when management’s priority has shifted toward repairing the balance sheet and preserving cash in Brazil.
For investors, the undisclosed price of the Saudi transaction remains the main missing piece. A meaningful cash consideration could strengthen the company’s restructuring efforts, while a low valuation would highlight the limited bargaining power of a seller under financial pressure.
The transactions do not by themselves resolve Oncoclínicas’ financial challenges, but they reduce two sources of uncertainty: an illiquid overseas minority investment and a disputed R$ 159 million receivable.
Leave a Reply